Genocea Biosciences, Inc.
GNCA
GNCA was delisted on the 2nd of June, 2022.
45 hedge funds and large institutions have $57.4M invested in Genocea Biosciences, Inc. in 2019 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 15 increasing their positions, 6 reducing their positions, and 14 closing their positions.
1,563% more call options, than puts
Call options by funds: $6.02M | Put options by funds: $362K
150% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 6
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
61% more capital invested
Capital invested by funds: $35.6M → $57.4M (+$21.7M)
36% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 14
10% more funds holding
Funds holding: 41 → 45 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$14.9M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$5.85M |
| 3 |
KCM
Kingdon Capital Management
New York
|
+$3.48M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.05M |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$1.83M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$1.18M |
| 3 |
FI
Fosun International
Hong Kong,
China
|
-$345K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$48K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$46.6K |
GNCA Hedge Fund Activity: Q2 2019 in Review
45 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q2 2019, worth a combined $57.4M — up 61% from $35.6M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new GNCA positions and 14 closed out — a net gain of 5 holders — while 15 added to existing stakes and 6 trimmed.
The largest buyer was NEA Management Company, adding an estimated $14.9M. The largest seller was Vivo Capital, cutting an estimated $1.83M.
- 45 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q2 2019, up from 41 in Q1 2019.
- Funds reported $57.4M of Genocea Biosciences, Inc. stock for Q2 2019, up 61% quarter-over-quarter.
- 19 funds opened new Genocea Biosciences, Inc. positions in Q2 2019 and 14 closed out, a net change of +5 holders.
- The largest Genocea Biosciences, Inc. buyer in Q2 2019 was NEA Management Company, an estimated $14.9M added.
- The largest Genocea Biosciences, Inc. seller in Q2 2019 was Vivo Capital, an estimated $1.83M sold.
Based on aggregated 13F filings for Q2 2019.